GREA is a Swiss network which promotes its vision and effective action to deal with addiction problem and drugs.

El GREA es una red suiza que promueve una acción eficaz sobre los problemas relacionados con la adicción y las drogas.

GREA est un réseau suisse qui promeut une action efficace pour les problèmes liés à l’usage et la dépendance à la drogue.

Groupement Romand d'Etudes des Addictions (GREA)

By Christoph Schindler, GREA - Groupement Romand d'Etudes des Addictions

While Prohibition remains in place in Switzerland, law enforcement is rather progressive compared to other latitudes: Using cannabis in public spaces attracts an administrative fine of 100 Swiss Francs (approx. USD$110), and the possession of up to 10 grammes is decriminalised. Despite its illegality, some 300,000 people of the country’s total population of 8.6 million currently use cannabis.

In September 2020, the Swiss parliament adopted a modification to the 

Federal Act on Narcotics and Psychotropic Substances

. The change provides a legal framework for a pilot project that would see legal and government-controlled supply initiatives established in 2021.

Restricted to cities having expressed an interest in joining the pilot.

Of a 5-year duration, with an option for a 2-year extension if requested by the local authority.

Limited to a total number of up to 5,000 adult participants (minimum 18 years old).

Available to people who can demonstrate that they are already using cannabis, and who agree to medical follow-up during the pilot project.

Prioritising, the use of local and organic cannabis, where possible.

The projects are expected to provide data on the use of cannabis by the Swiss and contribute to substantiating any potential future regulations.

A few days after its passing, a complimentary parliamentary initiative was submitted by a member of the National Council (the lower house of the Swiss legislature). The initiative aims to flesh out a political response to the regulation of cannabis, proposing standards similar to those in place for alcohol. This initiative responds directly to a statement by the Federal Council (the Swiss executive), which stated, in April 2018, that:

“The current ban on cannabis in the narcotics law, which aims to protect the population and promote abstinence, brings insufficient results. Despite this prohibition, consumption is not decreasing, the black market is growing, there is no quality control, and consumer safety is not guaranteed. Moreover, repression, which mobilises enormous resources, is not very effective.” FC 23.05.2018

The parliamentary initiative seeks to align itself with recommendations made by the 

, which had, in 2019, recommended the legal regulation of the cannabis market as a whole, from cultivation to trade to use. The initiative proposes to:

Take into consideration the Swiss “4-pillar approach” to drug policy (prevention, treatment, harm reduction and law enforcement).

Instruct authorities to control the production and trade of cannabis, in particular for the purpose of protecting young people and consumers, as well as informing.

Separate medical and non-medical markets.

Dry up the black market by ending prohibition.

Introduce a tax and regulate advertising.

Provide a framework for the production for personal use.

The text of the initiative relies on a regulation model developed by a multi-stakeholder forum, 

, a coalition representing five different interest groups: political parties, youth parties, prevention & healthcare specialists, the economic & environmental sectors, and networks of people who use drugs.. The coalition works toward bringing an alternative consensus to the current Swiss policy on cannabis, which maintains prohibition.

The regulation model by the coalition is based on two key dimensions: the protection of the population and the regulation of the market. It comprises the following aspects:

Promotion of harm reduction in relation to consumption.

Prevention and repression of conducts and specific work-related activities under the influence of cannabis.

Reduction of advertising and the presence of cannabis in the public space.

Control of the production and guaranteed traceability.

Separated markets for medical and non-medical products.

Sale of cannabis-related products in specialised stores.

Taxation of cannabis to finance supportive measures.

Monitoring of production for personal use.

A handful of cities, including Berne, Geneva, Zurich, Basel and Biel have already expressed interest in joining the pilot projects, mirroring interest in a similar pilot project in Dutch municipalities.

The pilot projects in Switzerland and the Netherlands, as well as Luxembourg’s regulatory plans, signal Europe will not be spared by the growing global trend towards regulation. The IDPC network recently launched Principles for the responsible legal regulation of cannabis, which seeks to ensure these moves serve the public interest, contribute to protect rights and advance social justice, and pre-empt corporate capture.

Switzerland set to launch cannabis pilot projects 2021

Switzerland’s current drug policy, founded on the 4 pillars, dates from the 1990s. In hindsight, it can be considered a success. Nevertheless, things have changed since then. Countries have adopted new legal frameworks and it is time for Switzerland to draw up a state of affairs report and to outline the drug policy that it wishes to promote and lead in the next ten years. The basis for this report lies in the request of the author of the Postulate (‘Postulat Rechsteiner’), to the Swiss government to draw up a state of affairs review of the country’s drug policy, taking into account the current developments at the national and international levels.

This report focuses on the developments that have taken place internationally and presents the current state of affairs regarding a certain number of countries’ drug policies, according to specific indicators. It complements the reports that the Federal Commission on Questions related to Addiction (CFLA) is producing on the adequacy of the Drug Law (LStup; RS812.121) and the relevant decrees, in light of scientific and social development of the past 10 years. Ultimately, this report will form part of the material which the Federal Council will rely upon to produce a report to Parliament by the end of 2019 on the perspectives of the Swiss drug policy for the next ten years.

The first question that needs to be addressed when examining the developments of the international drug control system is what exactly the international drug control system is. For the purposes of this paper, it is considered to mean the international bodies, mandated to specifically examine drug-related questions: the UN Office on Drugs and Crime (UNODC); the Commission on Narcotic Drugs (CND); and the International Narcotics Control Board (INCB). However, these bodies are not the only ones acting in the field of drugs in the international arena, as will be seen throughout this study. Other (health, human rights and other actors) are starting to address drug-related questions more closely, from their respective points of view.

Nevertheless, UNODC, INCB and CND remain the entities that are consistently referred to when discussing the international drug control regime. In fact, the three Drug Control Conventions (1961, 1971 and 1988) are considered the cornerstone of the international drug control system (Bewley-Taylor and Jelsma, 2012). Naturally, the system wouldn’t exist without State governments interacting with the international drug control system so they can also be considered part of the wider system.

Analysis of the international drug control system

Geneva is now occupying a new place in the international debate on drugs. The Drug Policy Week aims to connect relevant international and local actors with each other and to promote new synergies between them. Come take advantage of this unique opportunity to discuss, debate and share experiences with:

A dozen meetings made up of conferences, debates, film screenings and visits offered free of charge and open to the general public;

A multi-site organisation throughout Geneva, in English and French;

Many different topics such as confl icts, access to medicines, gender, health, human rights and the sustainable development goals.

The 2019 Commission on Narcotic Drugs’ Ministerial Segment: what does it mean for civil society advocacy? | Event page

 Uni Mail | Boulevard du Pont-d'Arve 40, Geneva, Switzerland


 Thursday, 27 June 2019 from 13:00-14:30 UTC+02

In March 2019, UN member states gathered in Vienna for a Ministerial Segment at the 62nd Session of the UN Commission on Narcotic Drugs (CND). The event aimed to take stock of the past decade of drug policy, since the adoption of the 2009 Political Declaration and Plan of Action on drugs, and look to the future for the next ten years of UN drug control.
The high-level event resulted in a Ministerial Declaration that provides a general framework for UN drug policy between 2019 and 2029. Both this Declaration, and the UN System Common Position on global drug policy adopted in November 2018, have important implications for the future civil society advocacy in Vienna and Geneva, as well as at country level.
This event will analyse the key wins and challenges of the Ministerial Segment and its Declaration, and discuss the implications of this and other key UN high-level documents on drug policy for civil society advocacy towards Geneva-based UN entities/processes, in particular the World Health Organization, the UN Human Rights Council (including its Universal Periodic Review process and Special Procedures) and key human rights treaty bodies. Speakers will include:

• Ann Fordham, Executive Director, International Drug Policy Consortium
• Khalid Tinasti, Executive Secretary, Global Commission on Drug Policy & Researcher at GSI at the University of Geneva
• Giada Girelli, Human Rights Analyst, Harm Reduction International
• Luciana Pol, Senior Fellow Security Policy and Human Rights, Centro de Estudios Legales y Sociales
• Judy Chang, Executive Director, International Network of People Who Use Drugs
Chair: Zaved Mahmood, Advisor on Human Rights and Drug Policy, Office of the High Commissioner for Human Rights

Geneva Drug Policy Week

The current upheavals in the global drug system have made Geneva an international forum for policy dialogue on psychoactive substances. In this context, GREA and the University of Geneva are launching a platform for exchanges on health and human rights, which aims to strengthen links in the global ecosystem but also to stimulate synergies with local resources.

This event will take place on June 26th at 17.30 at the Biotech Campus in Geneva as part of the international campaign "Support Don't Punish".

After an official party with representatives of the UN, the Global Commission, the IDPC and the Geneva addiction network, a film will be screened: "A day in the life" on drug use in the world. "A day in the life" will be broadcast in Geneva. Produced by the Drug Reporter team, a foundation that promotes risk reduction and drug policy reform, the documentary portrays eight users in their everyday lives. Destigmatising and touching, it shows their difficulties on a daily basis, the setting in which they evolve and against which they collide, the eyes of others. The film disintegrates myths and prejudices that one may have of people who consume while privileging the humanist approach. It can be ordered from GREA (celestine.perissinotto@grea.ch) for any distribution desired in the French-speaking institutions (subtitled in French).

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

Groupement Romand d'Etudes des Addictions (GREA)

Region

Translations

Related Content

Switzerland set to launch cannabis pilot projects 2021

Analysis of the international drug control system

Geneva Drug Policy Week

A new chapter for International Geneva: Drug policy